Opaleye Management Inc. Deciphera Pharmaceuticals, Inc. Transaction History

Opaleye Management Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$7.7 - $37.13 $1.58 Million - $7.63 Million	-205,381 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.73 - $47.95 $543,939 - $796,881	-16,619 Reduced 7.49%	205,381 $7.52 Million
Q1 2020 May 15, 2020	SELL	$33.63 - $69.4 $84,075 - $173,500	-2,500 Reduced 1.11%	222,000 $9.14 Million
Q4 2019 Feb 14, 2020	SELL	$31.7 - $69.93 $174,350 - $384,615	-5,500 Reduced 2.39%	224,500 $14 Million
Q3 2019 Nov 14, 2019	SELL	$19.95 - $38.85 $1.6 Million - $3.11 Million	-80,000 Reduced 25.81%	230,000 $7.81 Million
Q2 2019 Aug 14, 2019	SELL	$21.05 - $26.21 $631,500 - $786,300	-30,000 Reduced 8.82%	310,000 $6.99 Million
Q4 2018 Feb 14, 2019	SELL	$19.08 - $36.14 $1.53 Million - $2.89 Million	-80,000 Reduced 19.05%	340,000 $7.14 Million
Q2 2018 Aug 14, 2018	BUY	$20.06 - $44.95 $1.1 Million - $2.47 Million	55,000 Added 15.07%	420,000 $16.5 Million
Q1 2018 May 14, 2018	BUY	$20.04 - $29.71 $7.31 Million - $10.8 Million	365,000 New	365,000 $7.31 Million
Q4 2017 Feb 09, 2018	SELL	$16.54 - $24.2 $3.59 Million - $5.25 Million	-217,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$17.65 - $18.99 $3.83 Million - $4.12 Million	217,000	217,000 $4.12 Million

293K

500

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.